4 (vs 6) Cycles of Adjuvant Chemo Sufficient for Early Breast Cancer

Share this article:
(ChemotherapyAdvisor) – No evidence was found that extending adjuvant doxorubicin and cyclophosphamide or single-agent paclitaxel from 4 to 6 cycles improves clinical outcome in women with resected primary breast cancer and 0 to 3 positive nodes, the Cancer and Leukemia Group B 40101 study reported in a rapid communication in the Journal of Clinical Oncology online July 23.

The study enrolled 3,171 women with operable breast cancer and 0 to 3 positive nodes (94% were node-negative and 6% had 1 to 3 positive nodes) between 2002 and 2008 and randomly assigned them to either 4 or 6 cycles of either doxorubicin and cyclophosphamide or paclitaxel. Patients were stratified by estrogen receptor/progesterone receptor, HER2, and menopausal status.

The 4-year relapse-free survival at a median follow-up of 5.3 years was 90.9% for 6 cycles and 91.8% for 4 cycles (adjusted HR 1.03 [95% CI, 0.84–1.28]; P=0.77). The 4-year overall survival was 95.3% for 6 cycles and 96.3% for 4 cycles [HR 1.12 [95% CI, 0.84 to 1.49]; P=0.44). No interaction was observed between treatment duration and chemotherapy regimen, estrogen-receptor/progesterone receptor, or HER2 status on relapse-free or overall survival.

This study demonstrates that “…patients can be spared longer and more toxic treatment with these regimens without fear of compromising breast cancer outcome,” Lawrence N. Shulman, MD, of the Dana-Farber Cancer Institute, Boston, MA, and colleagues concluded.

Abstract

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

CTA Community Poll

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Breast Cancer

Clearview Diagnostics, Inc. to Develop Breast Cancer Screening Technology

Clearview Diagnostics, Inc. to Develop Breast Cancer Screening ...

Clearview Diagnostics, Inc. is developing new breast cancer screening technology that will allow for more widespread diagnosis.

Gene Signature Predicts Breast Cancer Response to Tamoxifen

Gene Signature Predicts Breast Cancer Response to Tamoxifen

Gene signature may be used to guide therapy for patients with ER-positive breast cancer.

US Patients Have Higher Breast Cancer Diagnosis Costs Than Those in Europe

US Patients Have Higher Breast Cancer Diagnosis Costs ...

European health authorities bought nearly 500,000 more biopsy needles for breast cancer at 60% of the amount spent in the US.